Karyopharm Therapeutics (KPTI) Revenue & Revenue Breakdown
Karyopharm Therapeutics Revenue Highlights
Latest Revenue (Y)
$145.24M
Latest Revenue (Q)
$29.52M
Main Segment (Y)
License and Service
Main Geography (Y)
CANADA
Karyopharm Therapeutics Revenue by Period
Karyopharm Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $145.24M | -0.55% |
| 2023-12-31 | $146.03M | -7.03% |
| 2022-12-31 | $157.07M | -25.14% |
| 2021-12-31 | $209.82M | 94.12% |
| 2020-12-31 | $108.08M | 164.31% |
| 2019-12-31 | $40.89M | 34.80% |
| 2018-12-31 | $30.34M | 1790.09% |
| 2017-12-31 | $1.60M | 942.21% |
| 2016-12-31 | $154.00K | -38.40% |
| 2015-12-31 | $250.00K | 9.17% |
| 2014-12-31 | $229.00K | -40.83% |
| 2013-12-31 | $387.00K | -38.96% |
| 2012-12-31 | $634.00K | 317.11% |
| 2011-12-31 | $152.00K | - |
Karyopharm Therapeutics generated $145.24M in revenue during NA 2024, up -0.55% compared to the previous quarter, and up 355.16% compared to the same period a year ago.
Karyopharm Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $29.52M | -31.01% |
| 2024-06-30 | $42.79M | 29.16% |
| 2024-03-31 | $33.13M | -1.84% |
| 2023-12-31 | $33.75M | -6.28% |
| 2023-09-30 | $36.01M | -4.18% |
| 2023-06-30 | $37.58M | -2.89% |
| 2023-03-31 | $38.70M | 15.24% |
| 2022-12-31 | $33.58M | -7.10% |
| 2022-09-30 | $36.15M | -8.91% |
| 2022-06-30 | $39.68M | -16.76% |
| 2022-03-31 | $47.67M | -62.25% |
| 2021-12-31 | $126.27M | 235.03% |
| 2021-09-30 | $37.69M | 66.76% |
| 2021-06-30 | $22.60M | -2.83% |
| 2021-03-31 | $23.26M | -33.73% |
| 2020-12-31 | $35.10M | 64.53% |
| 2020-09-30 | $21.33M | -36.35% |
| 2020-06-30 | $33.51M | 84.77% |
| 2020-03-31 | $18.14M | 0.23% |
| 2019-12-31 | $18.10M | 37.62% |
| 2019-09-30 | $13.15M | 38.51% |
| 2019-06-30 | $9.49M | 6024.52% |
| 2019-03-31 | $155.00K | -24.76% |
| 2018-12-31 | $206.00K | -13.81% |
| 2018-09-30 | $239.00K | -98.80% |
| 2018-06-30 | $19.89M | 98.91% |
| 2018-03-31 | $10.00M | 551.89% |
| 2017-12-31 | $1.53M | 100.00% |
| 2017-09-30 | - | -100.00% |
| 2017-06-30 | $3.00K | -95.59% |
| 2017-03-31 | $68.00K | 44.68% |
| 2016-12-31 | $47.00K | -2.08% |
| 2016-09-30 | $48.00K | -18.64% |
| 2016-06-30 | $59.00K | 100.00% |
| 2016-03-31 | - | -100.00% |
| 2015-12-31 | $25.00K | -66.67% |
| 2015-09-30 | $75.00K | -50.00% |
| 2015-06-30 | $150.00K | 100.00% |
| 2015-03-31 | - | -100.00% |
| 2014-12-31 | $15.00K | -28.57% |
| 2014-09-30 | $21.00K | - |
| 2014-06-30 | $21.00K | -87.72% |
| 2014-03-31 | $171.00K | 714.29% |
| 2013-12-31 | $21.00K | 100.00% |
| 2013-09-30 | - | -100.00% |
| 2013-06-30 | $133.00K | -42.92% |
| 2013-03-31 | $233.00K | 606.06% |
| 2012-12-31 | $33.00K | -2.94% |
| 2012-09-30 | $34.00K | - |
Karyopharm Therapeutics generated $29.52M in revenue during Q3 2024, up -31.01% compared to the previous quarter, and up 78.54% compared to the same period a year ago.
Karyopharm Therapeutics Revenue Breakdown
Karyopharm Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| License and Service | $28.01M | $24.36M | $15.67M | - | - |
| Health Care, Other | $2.74M | - | - | - | - |
| Royalty | - | $1.50M | $300.00K | - | - |
| License | - | $3.50M | - | - | - |
| License And Other | - | - | - | $111.38M | $31.88M |
| Product | - | - | - | $98.44M | $76.21M |
Karyopharm Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: License and Service (91.10%), and Health Care, Other (8.90%).
Quarterly Revenue by Product
| Product/Service | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Health Care, Other | $2.29M | $241.00K | $203.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| License and Service | $12.86M | $8.75M | $6.41M | $4.45M | $5.56M | $5.61M | $8.74M | $437.00K | $1.62M | $6.53M | - | - | - | - | - | - | - | - | - | - |
| Royalty | - | - | - | - | $1.50M | $400.00K | $200.00K | $1.00M | $1.40M | $1.00M | - | - | - | - | - | - | - | - | - | - |
| Other Royalty | - | - | - | - | $500.00K | $400.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| License And Other | - | - | - | - | - | - | - | - | - | - | $19.37M | $96.47M | $10.97M | $2.42M | $1.53M | $14.88M | $3.00K | $14.91M | $2.08M | $377.00K |
| Product | - | - | - | - | - | - | - | - | - | - | $28.30M | $29.80M | $26.72M | $20.18M | $21.73M | $20.22M | $21.33M | $18.60M | $16.06M | $17.72M |
Karyopharm Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: License and Service (84.86%), and Health Care, Other (15.14%).
Karyopharm Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 20 |
|---|---|
| CANADA | $5.00M |
Karyopharm Therapeutics's latest annual revenue breakdown by geography, as of Dec 20: CANADA (100.00%).
Karyopharm Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| KPTI | Karyopharm Therapeutics | $145.24M | $29.52M |
| CTMX | CytomX Therapeutics | $138.10M | $33.43M |
| GOSS | Gossamer Bio | $114.70M | $9.48M |
| BLUE | bluebird bio | $83.81M | $16.10M |
| GLUE | Monte Rosa Therapeutics | $75.62M | $4.70M |
| MRSN | Mersana Therapeutics | $40.50M | $12.60M |
| AGIO | Agios Pharmaceuticals | $36.50M | $8.96M |
| GBIO | Generation Bio | $19.89M | $4.09M |
| KRON | Kronos Bio | $9.85M | $2.37M |
| NUVB | Nuvation Bio | $7.87M | $727.00K |
| XFOR | X4 Pharmaceuticals | $2.56M | $560.00K |
| LYRA | Lyra Therapeutics | $1.53M | $195.00K |
| RLYB | Rallybio | $636.00K | $299.00K |
| REPL | Replimune Group | - | - |
| ABOS | Acumen Pharmaceuticals | - | - |
| NVCT | Nuvectis Pharma | - | - |
| HOOK | HOOKIPA Pharma | - | $4.70M |
| ASMB | Assembly Biosciences | - | $6.84M |
| PMVP | PMV Pharmaceuticals | - | - |
| MREO | Mereo BioPharma Group | - | - |